Literature DB >> 30135591

The association of nocturnal hypoxia and an echocardiographic measure of pulmonary hypertension in children with sickle cell disease.

Pritish Mondal1, Bryan Stefek2, Ankita Sinharoy3, Binu-John Sankoorikal4, Mutasim Abu-Hasan5, Vincent Aluquin2.   

Abstract

BACKGROUND: Pulmonary hypertension (PH) is multifactorial in origin and may develop early in children with sickle cell disease (C-SCD). Potential etiologies are hemolysis-induced endothelial dysfunction, left ventricular (LV) dysfunction, and chronic hypoxia. Nocturnal hypoxia (NH) in C-SCD is known to be a sequela of obstructive sleep apnea (OSA). The primary objective of this study is to correlate polysomnographic evidence NH with echocardiographic measures of PH in C-SCD.
METHODS: We performed a retrospective chart review of 20 C-SCD (Hemoglobin SS), who had polysomnography and echocardiogram performed within a narrow time interval, and 31% of them had pre-existing cardiac conditions. Tricuspid regurgitant jet velocity (TRJV) ≥ 2.5 m/s was considered as an indicator of PH.
RESULTS: Twenty-five percent of the subjects had NH. Forty percent of C-SCD, predominantly male, had evidence of PH based on an elevated TRJV. Children with NH compared to non-NH had significantly worse baseline hypoxemia (p < 0.001), higher TRJV (p = 0.005), and higher LV end-diastolic diameters (p = 0.009). The severity of NH was influenced by OSA. However, PH was not associated with OSA or duration of hydroxyurea therapy.
CONCLUSION: Our study indicates that NH is associated with PH in C-SCD, and that screening for NH may help to identify C-SCD with higher morbidity risk.

Entities:  

Mesh:

Year:  2018        PMID: 30135591     DOI: 10.1038/s41390-018-0125-6

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  1 in total

1.  Polysomnographic characteristics of a referred sample of children with sickle cell disease.

Authors:  Valerie E Rogers; Daniel S Lewin; Glenna B Winnie; Jeanne Geiger-Brown
Journal:  J Clin Sleep Med       Date:  2010-08-15       Impact factor: 4.062

  1 in total
  2 in total

1.  Inhibition of Band 3 tyrosine phosphorylation: a new mechanism for treatment of sickle cell disease.

Authors:  Panae Noomuna; Mary Risinger; Sitong Zhou; Katie Seu; Yuncheng Man; Ran An; Daniel A Sheik; Jiandi Wan; Jane A Little; Umut A Gurkan; Francesco M Turrini; Theodosia Kalfa; Philip S Low
Journal:  Br J Haematol       Date:  2020-04-28       Impact factor: 6.998

2.  Beneficial effects of adenotonsillectomy in children with sickle cell disease.

Authors:  Ilaria Liguoro; Michele Arigliani; Bethany Singh; Lisa Van Geyzel; Subarna Chakravorty; Cara Bossley; Maria Pelidis; David Rees; Baba P D Inusa; Atul Gupta
Journal:  ERJ Open Res       Date:  2020-10-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.